Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
6.
J Fam Pract ; 67(2): 107-109, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-29400902

RESUMEN

A 49-year-old Hispanic woman presented with a 4-month history of scaling and a macerated rash localized between her toes. The rash was malodorous, mildly erythematous, and sometimes associated with pruritus. The patient had no relevant medical history. Potassium hydroxide testing was performed and found to be negative. So a Wood's lamp was used to examine the patient's toes--and it revealed the diagnosis. WHAT IS YOUR DIAGNOSIS? HOW WOULD YOU TREAT THIS PATIENT?


Asunto(s)
Eritrasma/diagnóstico , Enfermedades del Pie/diagnóstico , Enfermedades del Pie/microbiología , Antibacterianos/uso terapéutico , Claritromicina/uso terapéutico , Diagnóstico Diferencial , Eritrasma/tratamiento farmacológico , Exantema/diagnóstico , Femenino , Enfermedades del Pie/tratamiento farmacológico , Humanos , Persona de Mediana Edad
8.
Dermatol Online J ; 23(5)2017 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-28537862

RESUMEN

BACKGROUND: Erythrasma is a benign dermatosis that typically occurs on intertriginous skin. PURPOSE: We describe a series of nine men with erythrasma that were successfully treated with mupirocin 2% ointment monotherapy. METHODS AND MATERIALS: We reviewed PubMed for the following terms: erythrasma, mupirocin, ointment, treatment. We also reviewed papers containing these terms and their references. RESULTS: Complete resolution of erythrasma occurred following monotherapy with twice daily application of mupirocin 2% ointment. CONCLUSIONS: Several topical and oral treatments are available to successfully manage erythrasma. Our series of patients with erythrasma experienced resolution with mupirocin 2% ointment treatment within 2 to 4 weeks of therapy. Monotherapy with mupirocin 2% ointment should be considered as a primary treatment alternative for erythrasma.


Asunto(s)
Antibacterianos/administración & dosificación , Eritrasma/tratamiento farmacológico , Mupirocina/administración & dosificación , Administración Cutánea , Adulto , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Eritrasma/patología , Humanos , Masculino , Persona de Mediana Edad , Pomadas , Resultado del Tratamiento
9.
Rev Med Inst Mex Seguro Soc ; 54(4): 458-61, 2016.
Artículo en Español | MEDLINE | ID: mdl-27197103

RESUMEN

BACKGROUND: Erythrasma is caused by Corinebacterium minutissimum producing a porphyrin that with Wood's light emits a coral-red fluorescence. It is the most common bacterial infection of the feet. Ozonated olive oil decreases the cytoplasm and damages bacterial proteins and lipids. Treatment is with oral erythromycin and there is no consensus regarding the topical therapy of choice. The aim of this paper is to evaluate the therapeutic efficacy of ozonated olive oil in a pilot trial for Erythrasma. METHODS: Experimental, open, observational, descriptive, longitudinal clinical trial at the section of Mycology, of the General Hospital "Dr. Manuel Gea González". PATIENTS: 10 individuals with interdigital feet Erythrasma. INTERVENTION: ozonated olive oil every 12 hours for 10 days was given. RESULTS: All patients had disappearance of coral-red fluorescence, erythema, fissures, pruritus, and maceration; two patients persisted with scaling. A cure was obtained in 100 % of patients, similar to oral erythromycin response. CONCLUSIONS: Ozonated olive oil is a good topical treatment option for interdigital Erythrasma avoiding oral medications. Larger studies are required.


Introducción: el eritrasma es causado por Corinebacterium minutissimum que produce una porfirina que con la luz de Wood emite una fluorescencia rojo coral es la infección bacteriana más frecuente en los pies. El aceite de oliva ozononificado disminuye el citoplasma y daña las proteínas y los lípidos bacterianos. El tratamiento es mediante eritromicina oral y no hay consenso respecto a la terapia tópica de elección. El objetivo de este trabajo es evaluar la eficacia terapéutica del aceite de oliva ozonificado en el eritrasma en una prueba piloto. Métodos: estudio clínico experimental, abierto, observacional, descriptivo y longitudinal, llevado a cabo en la sección de Micología del Hospital General "Dr. Manuel Gea González". Se incluyeron 10 pacientes con eritrasma interdigital de pies, a quines se les administró aceite de oliva ozonificado cada 12 horas por 10 días. Resultados: en todos los pacientes hubo desaparición de la fluorescencia rojo coral, eritema, fisuras, prurito y maceración; en dos de ellos persistió la descamación. Se obtuvo una cura clínica en el 100 % de los pacientes, respuesta similar a la eritromicina oral. Conclusiones: el aceite de oliva ozonificado es una buena opción terapéutica tópica para el eritrasma interdigital, que permite evitar la prescripción de medicamentos por vía oral. Se requieren estudios más extensos.


Asunto(s)
Eritrasma/tratamiento farmacológico , Dermatosis del Pie/tratamiento farmacológico , Aceite de Oliva/uso terapéutico , Fitoterapia , Administración Cutánea , Adolescente , Adulto , Anciano , Esquema de Medicación , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Ozono , Proyectos Piloto , Dedos del Pie , Resultado del Tratamiento , Adulto Joven
10.
Mycoses ; 56 Suppl 1: 38-40, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23574025

RESUMEN

A warm and moist environment is a common risk factor for erythrasma, a condition characterized by pruritic, scaly and erythematous tan patches on the skin. Here we report on a 13-year-old athletic student presenting with pruritus and mild burning on her left medial thigh, and subsequently diagnosed with erythrasma. The patient was successfully treated with a 5-day regimen of Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antifúngicos/administración & dosificación , Diflucortolona/análogos & derivados , Eritrasma/tratamiento farmacológico , Miconazol/análogos & derivados , Administración Tópica , Adolescente , Diflucortolona/administración & dosificación , Combinación de Medicamentos , Eritrasma/complicaciones , Eritrasma/patología , Femenino , Humanos , Inflamación/complicaciones , Inflamación/tratamiento farmacológico , Miconazol/administración & dosificación , Prurito/complicaciones , Prurito/tratamiento farmacológico , Muslo/patología , Resultado del Tratamiento
12.
J Dermatolog Treat ; 24(1): 70-4, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21923567

RESUMEN

UNLABELLED: Although erythrasma is a superficial skin infection, there is no consensus on the treatment model of erythrasma. OBJECTIVE: To compare the efficacy of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma in a double-blind, placebo-controlled, randomized trial. METHODS: Hundred and fifty-one patients over 18 years of age were included in this study. Patients were randomized and divided into five groups. They received clarithromycin, erythromycin, fusidic acid cream, placebo cream or placebo tablets. Patients were evaluated by Wood's light reflection scores and the initial score values and the values on the days of 2, 7 and 14 were compared statistically. RESULTS: According to the mean of Wood's light reflection scores, the efficacy of fusidic acid cream therapy was significantly higher than other therapies. When the efficacy of clarithromycin and erythromycin therapy was compared, clarithromycin therapy was significantly more effective than erythromycin therapy at 48 h. However, there was no statistical difference on the days of 7 and 14. CONCLUSION: Topical fusidic acid proved to be the most effective treatment; however, clarithromycin therapy may be an alternative regimen in the treatment of erythrasma because of its efficiency and better patient's compliance.


Asunto(s)
Antibacterianos/uso terapéutico , Claritromicina/uso terapéutico , Eritrasma/tratamiento farmacológico , Eritromicina/uso terapéutico , Ácido Fusídico/uso terapéutico , Enfermedades Cutáneas Bacterianas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Crema para la Piel , Resultado del Tratamiento , Adulto Joven
14.
J Infect ; 56(1): 77-9, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18036665

RESUMEN

Corynebacterium minutissimum, the causative agent of erythrasma, is a gram-positive, non-spore forming, aerobic or facultative anaerobic bacillus. It has rarely been associated with extracutaneous disease, since its description in 1961. A computerized medline search for review of literature was performed. To our knowledge, there have been 18 cases of C. minutissimum infections that caused conditions other than erythrasma. These include reports of cases of abscess formation, intravascular catheter-related bacteremias, ophthalmologic involvement, endocarditis, peritonitis, cutaneous granulomas, pyelonephritis in an infant and primary bacteremia with underlying hematologic malignancy. We report a rare case of bacteremia and meningitis due to C. minutissimum successfully treated with intravenous ampicillin.


Asunto(s)
Bacteriemia/microbiología , Corynebacterium/aislamiento & purificación , Eritrasma/microbiología , Meningitis/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Corynebacterium/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple , Eritrasma/tratamiento farmacológico , Humanos , Lactante , Masculino , Meningitis/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad
15.
Rev Med Liege ; 62(2): 67-70, 2007 Feb.
Artículo en Francés | MEDLINE | ID: mdl-17461292

RESUMEN

Intertrigo is a common inflammatory disorder of various origins. It can represent a single skin manifestation or be part of a disorder possibly exhibiting specific manifestations on other parts of the body. Hence, intertrigo may represent a sign of a peculiar disease. It may also result from physicochemical aggressions of the skin following occlusion of the large skinfolds particularly in case of stoutness. In this intance, a treatment similar to that of diaper dermatitis can be offered. A paste enriched or not with miconazole nitrate is indicated to prevent or treat most presentations of intertrigo.


Asunto(s)
Intertrigo/prevención & control , Obesidad/complicaciones , Administración Cutánea , Antiinfecciosos/administración & dosificación , Antiinfecciosos/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Dermatomicosis/tratamiento farmacológico , Eritrasma/tratamiento farmacológico , Humanos , Intertrigo/tratamiento farmacológico , Intertrigo/etiología , Miconazol/administración & dosificación , Miconazol/uso terapéutico , Cuidados de la Piel
16.
Photodermatol Photoimmunol Photomed ; 22(3): 153-6, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16719870

RESUMEN

BACKGROUND: Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. OBJECTIVES: Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. METHODS: Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. RESULTS: Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. CONCLUSION: We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.


Asunto(s)
Eritrasma/tratamiento farmacológico , Fotoquimioterapia , Fármacos Fotosensibilizantes/farmacología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fotoquimioterapia/métodos , Estudios Prospectivos , Inducción de Remisión , Resultado del Tratamiento
18.
Drugs ; 62(8): 1131-41, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12010076

RESUMEN

Corynebacterium minutissimum is the bacteria that leads to cutaneous eruptions of erythrasma and is the most common cause of interdigital foot infections. It is found mostly in occluded intertriginous areas such as the axillae, inframammary areas, interspaces of the toes, intergluteal and crural folds, and is more common in individuals with diabetes mellitus than other clinical patients. This organism can be isolated from a cutaneous site along with a concurrent dermatophyte or Candida albicans infection. The differential diagnosis of erythrasma includes psoriasis, dermatophytosis, candidiasis and intertrigo, and methods for differentiating include Wood's light examination and bacterial and mycological cultures. Erythromycin 250mg four times daily for 14 days is the treatment of choice and other antibacterials include tetracycline and chloramphenicol; however, the use of chloramphenicol is limited by bone marrow suppression potentially leading to neutropenia, agranulocytosis and aplastic anaemia. Further studies are needed but clarithromycin may be an additional drug for use in the future. Where there is therapeutic failure or intertriginous involvement, topical solutions such as clindamycin, Whitfield's ointment, sodium fusidate ointment and antibacterial soaps may be required for both treatment and prophylaxis. Limited studies on the efficacy of these medications exist, however, systemic erythromycin demonstrates cure rates as high as 100%. Compared with tetracyclines, systemic erythromycin has greater efficacy in patients with involvement of the axillae and groin, and similar efficacy for interdigital infections. Whitfield's ointment has equal efficacy to systemic erythromycin in the axillae and groin, but shows greater efficacy in the interdigital areas and is comparable with 2% sodium fusidate ointment for treatment of all areas. Adverse drug effects and potential drug interactions need to be considered. No cost-effectiveness data are available but there are limited data on cost-related treatment issues. A guideline is proposed for the detection, evaluation, treatment and prophylaxis of this cutaneous eruption.


Asunto(s)
Antibacterianos/uso terapéutico , Eritrasma/tratamiento farmacológico , Administración Oral , Administración Tópica , Antibacterianos/administración & dosificación , Corynebacterium/patogenicidad , Análisis Costo-Beneficio , Diagnóstico Diferencial , Interacciones Farmacológicas , Eritrasma/economía , Eritrasma/inmunología , Humanos , Pomadas , Calidad de Vida , Jabones
20.
Dermatol. rev. mex ; 41(4): 151-4, jul.-ago. 1997. ilus
Artículo en Español | LILACS | ID: lil-214269

RESUMEN

Se comentan los datos históricos, microbiológicos, patógenos y epidemiológicos del eritrasma, así como sus características clínicas y de laboratorio y su tratamiento. El agente causal es Corynebacterium minutissimum y se menciona que el eritrasma es una enfermedad común en nuestro medio, aunque se desconoce su frecuencia real. Es posible que sea mal diagnosticada o poco reportada debido a su relativamente fácil diagnóstico o a su favorable reacción ante los diversos tratamientos existentes


Asunto(s)
Humanos , Infecciones por Corynebacterium , Infecciones por Corynebacterium/diagnóstico , Corynebacterium/patogenicidad , Eritrasma , Eritrasma/diagnóstico , Eritrasma/tratamiento farmacológico , Eritrasma/historia , Eritrasma/microbiología , Rayos Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA